CAPRA findings (Conclusion) looks pretty good, especially for the Stage IV M1c patients, 64% BORR...
"At present No DLT’s have been observed in the first 26 patients receiving the combination treatment.
• Overall, adverse events have generally been low-grade constitutional symptoms related to CVA21 and standard pembrolizumab-related side effects. At present only two Grade 3 adverse events (hepatic toxicity and keratoacanthoma) related to pembrolizumab have been observed.
• CVA21-pembrolizumab combination therapy was associated with clinical benefit in treated patients.
• Preliminary Best Overall Response Rate (BORR) of 61.0% (14/23 pts) and 4/23 pts with Stable Disease.
• In patients with stage IV M1c disease a BORR of 64% (7/11 pts).
• Preliminary observations have revealed durable reductions in a number of injected and noninjected visceral/non-visceral lesions, with a number of patients displaying evidence of postinjection systemic exposure to CVA21."
- Forums
- ASX - By Stock
- VLA
- Ann: Viralytics to Present at 2017 SITC Annual Meeting
Ann: Viralytics to Present at 2017 SITC Annual Meeting, page-55
-
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)